Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sihuan Pharma Plans to Bring Anti-Infective Generics from India's Hetero Lab to China

publication date: Feb 12, 2020

Sihuan Pharma and Hetero Labs, an Indian generic drug maker, have signed a framework cooperation agreement to bring Hetero's products -- including potential COVID-19 anti-infectives -- to China. Hetero claims to be the leading producer of anti-retroviral drugs for HIV/AIDS, serving 40% of the HIV/AIDS population globally with 30 anti-retroviral product combinations. Sihuan, a novel drug company, will make and distribute Hetero's generic products in China. More details....

Stock Symbol: (HKEX: 0460)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here